Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)

Journal of Medicinal Chemistry

Volumn 50, Issue 4, 2007, Pages 794-806

  Sturino, Claudio F ^a   O'Neill, Gary ^a   Lachance, Nicolas ^a   Boyd, Michael ^a   Berthelette, Carl ^a   Labelle, Marc ^a   Li, Lianhai ^a   Roy, Bruno ^a   Scheigetz, John ^a   Tsou, Nancy ^b   Aubin, Yves ^a   Bateman, Kevin P ^a   Chauret, Nathalie ^a   Day, Stephen H ^a   Lévesque, Jean François ^a   Seto, Carmai ^a   Silva, Jose H ^a   Trimble, Laird A ^a   Carriere, Marie Claude ^a   Denis, Danielle ^a   Greig, Gillian ^a   Kargman, Stacia ^a   Lamontagne, Sonia ^a   Mathieu, Marie Claude ^a   Sawyer, Nicole ^a   Slipetz, Deborah ^a   Abraham, William M ^c   Jones, Tom ^a   McAuliffe, Malia ^a   Piechuta, Hana ^a   Nicoll Griffith, Deborah A ^a   Wang, Zhaoyin ^a   Zamboni, Robert ^a   Young, Robert N ^a   Metters, Kathleen M ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 (4 CHLOROBENZYL) 5 (1 HYDROXYETHYL) 7 (METHYLSULFONYL) 1,2,3,4 TETRAHYDROCYCLOPENTA[B]INDOL 3 YL]ACETIC ACID; [4 (4 CHLOROBENZYL) 7 FLUORO 5 (METHYLSULFONYL) 1,2,3,4 TETRAHYDROCYCLOPENTA[B]INDOL 3 YL]ACETIC ACID; [5 ACETYL 4 (4 CHLOROBENZYL) 7 (METHYLSULFONYL) 1,2,3,4 TETRAHYDROCYCLOPENTA[B]INDOL 3 YL]ACETIC ACID; INDOLEACETIC ACID; MESYLIC ACID DERIVATIVE; MK 0524; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; BILIARY EXCRETION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT;

AIRWAY OBSTRUCTION; ANIMALS; BILE; BINDING, COMPETITIVE; DOGS; HEPATOCYTES; HUMANS; INDOLES; MACACA FASCICULARIS; MALE; MICE; MICROSOMES; NASAL DECONGESTANTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SHEEP; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847345910     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0603668     Document Type: Article

References (50)

1. (a) Howarth, P. H. Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin. Exp. Allergy 1990, 20 (Suppl 2), 31-41.
2. (b) White, M. V.; Kaliner, M. A. Mediators of allergic rhinitis. J Allergy Clin. Immunol. 1992, 90, 679-704.
3. (c) White, M. V.; Kaliner, M. A. Histamine in allergic diseases. Clin. Allergy Immunol. 1996, 7, 61-90.
4. 2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Int. Arch. Allergy Immunol. 1996, 109, 161-166.
5. 4 receptor antagonist, MK-571. Can. J. Physiol. Pharmacol. 1989, 67, 845-850.
6. For reports of montelukast in treating allergic rhinitis, see: (b) Meltzer, E. O.; Malmstrom, K.; Lu, S.; Prenner, B. M.; Wei, L. X.; Weinstein, S. F.; Wolfe, J. D.; Reiss, T. F. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. J. Allergy Clin. Immunol. 2000, 105, 917-922.
7. (c) Van Adelsberg, J.; Philip, G.; Pedinoff, A. J.; Meltzer, E. O.; Ratner, P. H.; Menten, J.; Reiss, T. F. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003, 58, 1268-1276.
8. 2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 1982, 129, 1627-1631.
9. Park, Y-.J.; Baraniuk, J. N. Mechanisms of allergic rhinitis. Clin. Allergy Immunol. 2002, 16, 275-293.
10. Doyle, W. J.; Boehm, S.; Skoner, D. P. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J. Allergy Clin. Immunol. 1990, 86, 924-935.
11. Naclerio, R. M.; Meier, H. L.; Kagey-Sobotka, A.; Adkinson, N. F., Jr.; Meyers, D. A.; Norman, P. S.; Lichtenstein, L. M. Mediator release after nasal airway challenge with allergen. Am. Rev. Respir. Dis. 1983, 128, 597-602.
12. 2 as a mediator of allergic rhinitis. Science 2000, 287, 2013-2017.
13. (a) Trottein, F.; Faveeuw, C.; Gosset, P.; Angeli, V. Role of the D prostanoid receptor 1 in the modulation of immune and inflammatory responses. Crit. Rev. Immunol. 2004, 24 (5), 349-362.
14. (b) Kabashima, K.; Narumiya, S. The DP receptor, allergic inflammation and asthma. Prostaglandins, Leukotrienes Essent. Fatty Acids 2003, 69, 187-194.
15. For reports of other DP receptor antagonists, see: (a) Giles, H.; Leff, P.; Bolofo, M. L.; Kelly, M. G.; Robertson, A. D. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol. 1989, 96, 291-300.
16. (b) Torisu, K.; Kobayashi, K.; Iwahashi, M.; Egashira, H.; Nakai, Y.; Okada, Y.; Nanbu, F.; Ohuchida, S.; Nakai, H.; Toda, M. Development of a prostaglandin D2 receptor antagonist: Discovery of a new chemical lead. Eur. J. Med. Chem. 2005, 40, 505-519.
17. 2 receptor antagonists. 2. 6,6-Dimethylbicyclo[3.1.1]heptane derivatives. J. Med. Chem. 2003, 46, 2446-2455.
18. (d) Mitsumori, S.; Tsuri, T.; Honma, T.; Hiramatsu, Y.; Okada, T.; Hashizume, H.; Inagaki, M.; Arimura, A.; Yasui, K.; Asanuma, F.; Kishino, J.; Ohtani, M. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.1.1] heptane derivatives. J. Med. Chem. 2003, 46, 2436-2445.
19. 2 receptor antagonists. J. Med. Chem. 1997, 40, 3504-3507.
20. 2 receptor antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 3043-3048.
21. (b) Berthelette, C.; Lachance, N.; Li, L.; Sturino, C.; Wang, Z. Fluoro substituted cycloalkanoidindoles, compositions containing such compounds and methods of treatment using them. Patent Application WO 2003062200 A2, 2003; Chem. Abstr. 2003, 139, 149524.
22. 2 receptor1 suppresses iiicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6682-6687.
23. Sy, W.-W. Iodination of aromatic amines with iodine and silver sulfate. Synth. Commun. 1992, 22, 3215-3219.
24. Chen, C.; Lieberman, D. R.; Larsen, R. D.; Verhoeven, T. R.; Reider, P. J. Syntheses of indoles via a palladium-catalyzed annulation between iodoanilines and ketones. J. Org. Chem. 1997, 62, 2672-2677.
25. Lachance, N.; Chan, W. Y. Efficient synthesis of bromocyclopenta[b] indoles via a bromination-reduction sequences. J. Heterocycl. Chem. 2003, 40, 289-295.
26. A active ligands by the Stille process. Tetrahedron Lett. 1997, 38, 8453-8456.
27. RN1 reactions. Bull. Soc. Chim. Fr. 1995, 132, 306-313.
28. (a) Baskin, J. M.; Wang, Z. A mild, convenient synthesis of sulfinic acid salts and sulfonamides from alkyl and aryl halides. Tetrahedron Lett. 2002, 43, 8479-8483.
29. (b) Baskin, J. M.; Wang, Z. An efficient copper catalyst for the formation of sulfones from sulfinic acid salts and aryl iodides. Org. Lett. 2002, 4, 4423-4425.
30. (c) Suzuki, H.; Abe, H. Copper-assisted displacement reaction of nonactivated iodoarenes with arenesulfinates. Convenient alternative synthesis of unsymmetrical diaryl sulfones. Tetrahedron Lett. 1995, 36, 6239-6242.
31. 2 receptor antagonist. J. Org. Chem. 2005, 70, 268-274. This structure has been deposited with the Cambridge Crystallographic Data Centre (CCDC601363), and further crystallographic details are available in the Supporting Information.
32. Abramovitz, M.; Adam, M.; Boie, Y.; Carriere, M.; Denis, D.; Godbout, C.; Lamontagne, S.; Rochette, C.; Sawyer, N.; Tremblay, N. M.; Belley, M.; Gallant, M.; Dufresne, C.; Gareau, Y.; Ruel, R.; Juteau, H.; Labelle, M.; Ouimet, N.; Metters, K. M. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 2000, 1483 (2), 285-293.
33. Coleman, R. A.; Smith, W. L.; Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46, 205-229.
34. b Vehicle 0.5% methocel; dose volume 10 mL/kg; n = 2.
35. Li, C.; Chauret, N.; Trimble, L. A.; Nicoll-Griffith, D. A.; Silva, J. M.; MacDonald, D.; Perrier, H.; Yergey, J. A.; Parton, T.; Alexander, R. P.; Warrellow, G. J. Investigation of the in vitro metabolism profile of a phospodiesterase-IV inhibitor, CDP-840: Leading to structural optimization. Drug Metab. Dispos. 2001, 29, 232-241.
36. Nicoll-Griffith, D. A.; Gupta, N.; Twa, S. P.; Williams, H.; Trimble, L. A.; Yergey, J. A. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile. Drug Metab. Dispos. 1995, 23, 1085-1093.
37. Studies directed at addressing the potential role of transporters in the biliary clearance of antagonists 6 and 7 are currently on-going. Details of these investigations will be reported in due course.
38. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie, T. A. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17, 3-16.
39. 14C radiolabeled 11 and 12 will be reported elsewhere.
40. Day, S. H.; Mao, A.; White, R.; Schulz-Utermoehl, T.; Miller, R.; Beconi, M. G. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol. Toxicol. Methods 2005, 52, 278-285.
41. The structure of 20, the enantiomer of 13, is as follows: (Diagram presented).
42. 2. J. Exp. Med. 2001, 193, 255-261.
43. (b) Monneret, G.; Gravel, S.; Diamond, M.; Rokach, J.; Powell, W. S. Prostaglandin DT is a potent chemoattractant for human eosinophils that act via a novel DP receptor. Blood 2001, 98, 1942-1948.
44. 2. Br. J. Pharmacol. 2002, 137, 1163-1172.
45. Abraham, W. M.; Ahmed, A.; Ahmed, T.; Atkins, N. Anderson, P. Pharmacological evaluation of an allergic rhinitis model. Am. J. Respir. Crit. Care Med. 1998, 157, A616.
46. Jones, T. R.; Savoie, C.; Robichaud, A.; Sturino, C.; Scheigetz, J.; Lachance, N.; Roy, B.; Boyd, M.; Abraham, W. M. Studies with a DP receptor antagonist in sheep and guinea pig models of allergic rhinitis. Am. J. Respir. Crit. Care Med. 2003, 167, A218.
47. Abraham, W. M. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm. Pharmacol. Ther., in press.
48. No significant inhibition of the major cyctochrome P450 enzymes (1A2, 3A4, 2D6, 2C9) was observed with 13.
49. 2 on some isolated smooth muscle preparations. Br. J. Pharmacol. 1981, 73, 773-778.
50. 3H] U46619 to washed human platelets. Prostaglandins 1987, 33, 789-797.